Digest Network Come funziona
Network
/
Società
My
Non verificato

Mythic Therapeutics

Di cosa scriviamo

BiotecnologiaEventiFarmaceuticaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati
31/05/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Fiere
Eventi
Industria
Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
Fonte
Mythic Therapeutics
Emittente
Business Wire
1.00
0
22/05/2025
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer
Fonte
Mythic Therapeutics
Emittente
Business Wire
1.00
0
01/05/2025
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mythic Therapeutics to Present Updated Dose Escalation Data from Phase 1 KisMET-01 Study on MYTX-011 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Fonte
Mythic Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mythic Therapeutics Presents Preclinical Data Demonstrating Potent Efficacy of MYTX-011 Across a Broad Range of Tumor Xenograft Models Harboring Clinically Relevant Mutations at the American Association for Cancer Research (AACR) Annual Meeting
Fonte
Mythic Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0